Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Three-way split coming at BoE

Mon, 12th Dec 2022 11:25

STOXX down 0.4%, volatility hits 1-mo high

*

Caution ahead of central bank meetings

*

CHR Hansen rallies on Novozymes merger

*

U.S. stock index futures inch higher

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

THREE WAY SPLIT COMING AT BOE (1125 GMT)

The Bank of England's rate-setting Monetary Policy Committee could break in at least three different ways at its Thursday meeting, making assessing the implications complicated for investors.

A 50-basis point increase is the most likely outcome according to both by market pricing and a Reuters poll of analysts, but the process of getting there could be messy.

"A three-way-split looks likely to us, which might make discerning whether this is a ‘hawkish’ or ‘dovish’ 50bp more difficult," say analysts at BNP Paribas, who anticipate 50 basis points.

They say a recent speech by policy maker Silvana Tenreyro "seemed to indicate she could vote for unchanged rates next week," and speculate MPC newcomer Swati Dhingra "could also vote for a smaller increment than consensus."

Meanwhile, NatWest Markets forecast a 75-basis point increase, noting "The leading hawks, (Catherine) Mann & (Jonathan) Haskel, sound sufficiently concerned about embedded inflation risks. Deputy Governor (Dave) Ramsden appears to be leaning that way too."

NatWest say a majority for 75 bps appears come down to the votes of Governor Andrew Bailey and Deputy Governors Ben Broadbent and Jon Cunliffe.

Goldman expect a 7-2 split in favour of 50 bps with Tenreyro and Dhingra voting for 25.

What does that all mean? Who knows.

WHAT TO PREFER IN 2023: EUROPE OR AMERICA? (1043 GMT)

With European stocks heading into 2023 at a near-record discount to their Wall Street peers, the evergreen question of which market will beat the other looks more alive than ever.

Bernstein is betting on the Old World.

It believes investors should tactically overweight the region versus the U.S., principally based on expectations of a bigger potential of multiple expansion in Europe.

"If one assumes a benign scenario where inflation has peaked and that central banks remain careful but don't get much more hawkish, and that the energy crisis does not worsen from here, our view is that Europe is in a better position for multiple expansion," say Bernstein's Sarah McCarthy and Mark Diver.

According to Bernstein, Europe and the U.S. should both see further earnings cuts. But as markets typically bottom out a couple of months before earning cuts do, this should set the scene for recovery.

Add to that a higher rate environment, which tends to be tougher for growth-oriented regions like the U.S., and the extremely depressed sentiment around Europe, then Bernstein's case for Europe is clear.

Europe has seen outflows since 2016, whereas the U.S. has received strong inflows since end-2020, Bernstein says. In 2022 alone, investors have pulled out $100 billion from European equity funds and poured over $200 billion into the U.S..

According to Refinitiv Datastream, the MSCI Europe index trades at near record PE discount of 33.6% relative to the MSCI USA. That is well below the 5-year average discount of 23.7%.

And in in term of price perfomance, MSCI Europe trades just above the record low relative the MSCI USA hit in September.

VOLATILITY PICKS UP, STOXX DIPS (0906 GMT)

Caution over a flurry of fresh rate hikes this week, which will tighten financial conditions even further, was tangible in early trading in Europe with a gauge of equity volatility hitting a one-month high as the STOXX 600 benchmark slid.

The pan-European index was last down 0.7%, partly reversing Friday's gains, and the euro volatility index, a local equivalent of Wall Street's so-called fear gauge VIX , approached 23 points and hit its highest since Nov. 10. Most STOXX sectors were in the red, led by rate-sensitive real estate, down more than 2%.

Deal-making gave fuel to the biggest stock movers. CHR Hansen soared 36% at one point after the Danish food ingredients and enzymes maker was valued at a premium in a merger deal with peer with Novozymes.

London Stock Exchange was the second biggest gainer on the STOXX, up around 4%, following a cloud deal with Microsoft that saw the U.S. tech group taking a stake in the UK bourse operator.

Momentum continued for aerodefence plays set to benefit from higher military spending. A sectoral gauge surged to its highest since February 2020, up 0.8% to defy the broader weakness. Here is your opening snapshot:

EUROPE SEEN WEAKER AS MORE RATE HIKES LOOM (0740 GMT)

European shares are set to kick off a macro-packed week on the back foot, tracking Friday's late losses on Wall Street and weakness earlier in Asia, where spreading COVID cases in China added to the downbeat mood.

EuroSTOXX50, DAX and FTSE futures fell between 0.3 and 0.5%, while the MSCI's broadest index of Asia-Pacific shares outside Japan fell 1.3%. U.S. futures meanwhile pointed to softer start on Wall Street.

On the European corporate news front, shares in London Stock Exchange will be in focus after Microsoft agreed to take 4% in the UK exchange operator as part of deal to migrate the bourse operator's data platform into the cloud.

Eyes also on Sanofi after the French health group dropped plans to bid for Horizon Therapeutics, while in Italy, Tod's founder ditched plans to delist the shoemaker after a buy-out that didn't meet a key threshold.

Still in M&A, Superdry is another one to watch after the Sunday Times reported CEO and founder Julian Dunkerton has held talks with private equity firms about a possible buyout.

HUNKERING DOWN (0659 GMT)

Just as China faces a testing time over its dramatic COVID-19 policy pivot, financial markets are on full alert ahead of interest rate decisions coming out this week from the world's top central banks.

Initial market enthusiasm over China's easing of its stringent "zero-COVID" measures has now switched to worries over a wave of infections likely disrupting the economy.

European stock markets are set for a weaker start on Monday, dragged by declines in Asian stocks, with the spotlight on a series of central bank meetings even as expectations rise that euro zone inflation is peaking.

The European Central Bank is set to take its deposit rate up by 50 basis points to 2%, despite the euro zone economy almost certainly being in recession, as it battles inflation running at five times its target, a Reuters poll found.

It's a Super Thursday this week, with the ECB, Bank of England, and the Swiss and Norwegian central banks also expected to jack up borrowing costs. What markets are keen to find out is whether they are nearly done.

On Sunday, U.S. Treasury Secretary Janet Yellen forecast a substantial reduction in U.S. inflation in 2023, barring an unexpected shock.

Whether inflation is responding to the most aggressive Fed hiking cycle since the 1980s will be evident in this week's U.S. consumer price index report. On the corporate front, while French health group Sanofi announced it had dropped its bid for biotech company Horizon Therapeutics, the Wall Street Journal reported that Amgen is in advanced talks to buy Horizon.

Meanwhile, a consolidation is shaping up in the food delivery market as Turkish delivery company Getir bought German rival Gorillas in a deal worth $1.2 billion, merging two of the remaining companies in Europe promising groceries in minutes.

Key developments that could influence markets on Monday:

Economic data: UK October GDP and industrial output

More News
13 Jun 2022 09:09

Sanofi says next-gen COVID booster shot has potential against main variants

PARIS, June 13 (Reuters) - French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

Read more
10 Jun 2022 09:33

GSK closer to cracking elusive vaccine for common respiratory virus

LONDON, June 10 (Reuters) - GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.

Read more
30 May 2022 17:34

European shares rise as China growth hopes boost luxury, tech stocks

May 30 (Reuters) - European shares touched their highest level in almost a month on Monday, with optimism buoyed by China's easing of COVID-19 restrictions and adding of new stimulus.

Read more
25 May 2022 11:03

French health body backs new COVID vaccine booster campaign for this autumn

PARIS, May 25 (Reuters) - France's Haute Autorite de Sante (HAS) health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab.

Read more
28 Apr 2022 16:17

Strong earnings spur rally across European stocks

April 28 (Reuters) - European shares moved further off six-week lows hit last session as forecast-beating results from companies including energy major TotalEnergies and automaker Volvo Car helped set aside worries about slowing global economic growth.

Read more
30 Mar 2022 09:01

What to own in uncertain times

WHAT TO OWN IN UNCERTAIN TIMES (0859 GMT)

Read more
17 Mar 2022 13:56

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert on Thursday said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and the start of July, potentially paving the way for approval this summer.

Read more
17 Mar 2022 13:34

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and July this year, potentially paving the way for a decision by the summer.

Read more
14 Mar 2022 10:18

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Sanofi's shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker's drug development prowess.

Read more
14 Mar 2022 09:11

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Read more
23 Feb 2022 15:31

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 12:44

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 10:22

Healthcare companies Sanofi and GSK to seek COVID-19 vaccine regulatory approval

PARIS, Feb 23 (Reuters) - Healthcare companies Sanofi and GSK said they intend to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Read more
18 Feb 2022 09:00

GSK pauses trial of respiratory virus vaccine in pregnant women

Feb 18 (Reuters) - GSK has paused a late-stage trial of its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.